日本高潮视频在线观看-亚洲中文字幕永不卡-精品亚洲一区二区三区-伦理片夜夜躁狠狠躁日日躁-日本最新免费不卡二区-国产精品口爆一区二区三区-av一区二区三区高清-大鸡巴疯狂抽插小穴视频-日韩中文国产在线观看免费视频

Your Good Partner in Biology Research

重組蛋白

產(chǎn)品名稱 貨號(hào) 規(guī)格
Recombinant Thermotoga neapolitana UPF0042 nucleotide-binding protein CTN_0898 (CTN_0898) CSB-YP496321TNL
CSB-EP496321TNL
CSB-BP496321TNL
CSB-MP496321TNL
CSB-EP496321TNL-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Thermotoga neapolitana UvrABC system protein B (uvrB), partial CSB-YP496322TNL
CSB-EP496322TNL
CSB-BP496322TNL
CSB-MP496322TNL
CSB-EP496322TNL-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Thermotoga neapolitana 50S ribosomal protein L16 (rplP) CSB-YP496323TNL
CSB-EP496323TNL
CSB-BP496323TNL
CSB-MP496323TNL
CSB-EP496323TNL-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Thermotoga neapolitana 30S ribosomal protein S5 (rpsE) CSB-YP496324TNL
CSB-EP496324TNL
CSB-BP496324TNL
CSB-MP496324TNL
CSB-EP496324TNL-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Thermotoga neapolitana Pseudouridine-5'-phosphate glycosidase (psuG) CSB-YP496325TNL
CSB-EP496325TNL
CSB-BP496325TNL
CSB-MP496325TNL
CSB-EP496325TNL-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Thermotoga neapolitana Histidinol-phosphate aminotransferase (hisC) CSB-YP496326TNL
CSB-EP496326TNL
CSB-BP496326TNL
CSB-MP496326TNL
CSB-EP496326TNL-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Thermotoga neapolitana Ribosomal RNA small subunit methyltransferase H (rsmH) CSB-YP496327TNL
CSB-EP496327TNL
CSB-BP496327TNL
CSB-MP496327TNL
CSB-EP496327TNL-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Thermotoga neapolitana Methylenetetrahydrofolate--tRNA- (uracil-5-)-methyltransferase TrmFO CSB-YP496328TNL
CSB-EP496328TNL
CSB-BP496328TNL
CSB-MP496328TNL
CSB-EP496328TNL-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Thermotoga neapolitana Trigger factor (tig) CSB-YP496329TNL
CSB-EP496329TNL
CSB-BP496329TNL
CSB-MP496329TNL
CSB-EP496329TNL-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Thermotoga neapolitana Ketol-acid reductoisomerase (ilvC) CSB-YP496330TNL
CSB-EP496330TNL
CSB-BP496330TNL
CSB-MP496330TNL
CSB-EP496330TNL-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Thermotoga neapolitana Proline--tRNA ligase (proS), partial CSB-YP496331TNL
CSB-EP496331TNL
CSB-BP496331TNL
CSB-MP496331TNL
CSB-EP496331TNL-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Thermotoga neapolitana Probable endonuclease 4 (nfo) CSB-YP496332TNL
CSB-EP496332TNL
CSB-BP496332TNL
CSB-MP496332TNL
CSB-EP496332TNL-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Thermotoga neapolitana L-arabinose isomerase (araA) CSB-YP496333TNL
CSB-EP496333TNL
CSB-BP496333TNL
CSB-MP496333TNL
CSB-EP496333TNL-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Campylobacter lari 30S ribosomal protein S18 (rpsR) CSB-YP496334CZB
CSB-EP496334CZB
CSB-BP496334CZB
CSB-MP496334CZB
CSB-EP496334CZB-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Campylobacter lari Leucine--tRNA ligase (leuS), partial CSB-YP496335CZB
CSB-EP496335CZB
CSB-BP496335CZB
CSB-MP496335CZB
CSB-EP496335CZB-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Campylobacter lari Sec-independent protein translocase protein TatA (tatA), partial CSB-YP496336CZB
CSB-EP496336CZB
CSB-BP496336CZB
CSB-MP496336CZB
CSB-EP496336CZB-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Campylobacter lari 4-hydroxy-3-methylbut-2-enyl diphosphate reductase (ispH) CSB-YP496337CZB
CSB-EP496337CZB
CSB-BP496337CZB
CSB-MP496337CZB
CSB-EP496337CZB-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Campylobacter lari Holliday junction ATP-dependent DNA helicase RuvB (ruvB) CSB-YP496338CZB
CSB-EP496338CZB
CSB-BP496338CZB
CSB-MP496338CZB
CSB-EP496338CZB-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Campylobacter lari Peptidyl-tRNA hydrolase (pth) CSB-YP496339CZB
CSB-EP496339CZB
CSB-BP496339CZB
CSB-MP496339CZB
CSB-EP496339CZB-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Campylobacter lari 50S ribosomal protein L31 (rpmE) CSB-YP496340CZB
CSB-EP496340CZB
CSB-BP496340CZB
CSB-MP496340CZB
CSB-EP496340CZB-B
20μg/100μg/1mg(1mg*1 or 500ug*2)

有用資源

什么是重組蛋白?

重組蛋白是一種可操縱的蛋白質(zhì)形式,可以通過多種方式產(chǎn)生大量蛋白質(zhì)、修改基因序列和制造有用的商業(yè)產(chǎn)品。重組蛋白的技術(shù)資源在重組蛋白的開發(fā)過程中,除了表達(dá)系統(tǒng)之外,還面臨著一系列令人困惑的選擇,如表達(dá)載體的選擇、表達(dá)蛋白的長度(全長或部分)、是否帶標(biāo)簽等。在生產(chǎn)重組蛋白時(shí),你必須做出很多決定。如果你選擇的明智,你將獲得高質(zhì)量的重組蛋白,后續(xù)的實(shí)驗(yàn)更有可能成功。但是如果你做了錯(cuò)誤的決定,你可能得不到你所需要的重組蛋白或者重組蛋白的質(zhì)量和純度不符合要求。在這里,來自CUSABIO的蛋白表達(dá)工程師根據(jù)他們開發(fā)重組蛋白的經(jīng)驗(yàn)總結(jié)出了幾個(gè)有用的提示,可以幫助你做出明智的決策。

第一條:重組蛋白的生產(chǎn),在這篇文章中,我們旨在闡明重組蛋白的定義以及如何生產(chǎn)重組蛋白。

第二條:如何選擇合適的表達(dá)載體?

表達(dá)載體是一種DNA分子,它攜帶特定的基因進(jìn)入宿主細(xì)胞,并利用細(xì)胞的蛋白質(zhì)合成機(jī)制來產(chǎn)生由該基因編碼的蛋白質(zhì)。表達(dá)載體可使外源基因在宿主細(xì)胞中高效表達(dá),經(jīng)過多年的發(fā)展,表達(dá)載體已成為一種成熟而受歡迎的生物技術(shù)。在重組蛋白生產(chǎn)過程中是一種基本成分。正如標(biāo)題所示,本文主要總結(jié)了幾個(gè)有用的技巧來選擇合適的表達(dá)載體。

第三條:如何表達(dá)具有生物活性的蛋白質(zhì)?

根據(jù)重組蛋白的不同應(yīng)用,對(duì)其生物活性有不同的要求。但是我們?nèi)绾未_保蛋白質(zhì)的產(chǎn)生具有生物活性呢?本文將圍繞這個(gè)主題,并提供一些解決方案。除了以上文章,我們還收集了一些重組蛋白的常見問題。您可以單擊以下鏈接查看。http://m.bdspa.cn/technology-91.html。此外,我們還為我們的客戶提供重組蛋白表達(dá)服務(wù),您可以點(diǎn)擊這里獲取更多信息。注:如果您對(duì)CUSABIO的蛋白質(zhì)有任何疑問,涉及到蛋白質(zhì)的價(jià)格、交貨、質(zhì)量等,您可以點(diǎn)擊橙色按鈕為我們?cè)诰€留言。

引用資料

Recombinant Severe acute respiratory syndrome coronavirus 2 RNA-dependent RNA polymerase(NSP12) cited in "SARS-CoV-2 hijacks cellular kinase CDK2 to promote viral RNA synthesis". Signal transduction and targeted therapy, 2023

Recombinant Mouse Mixed lineage kinase domain-like protein(Mlkl) cited in "OASL phase condensation induces amyloid-like fibrillation of RIPK3 to promote virus-induced necroptosis". Nature cell biology, 2023

Recombinant Mouse Proto-oncogene c-Fos(Fos) cited in "Dihydroartemisinin imposes positive and negative regulation on Treg and plasma cells via direct interaction and activation of c-Fos". Communications biology, 2023

Recombinant Human Keratin, type I cytoskeletal 18(KRT18) cited in "Calcitonin gene-related peptide ameliorates sepsis-induced intestinal injury by suppressing NLRP3 inflammasome activation". International immunopharmacology, 2023

Recombinant Human Protein Wnt-5a (WNT5A) cited in "ATBF1 is a potential diagnostic marker of histological grade and functions via WNT5A in breast cancer". BMC Cancer, 2022

Read More >>



×